Hydroxychloroquine COVID trial halted after just 17 patients
NCT ID NCT04345692
First seen Feb 06, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This study aimed to see if hydroxychloroquine could help hospitalized COVID-19 patients recover faster. It planned to enroll 350 adults but was stopped early after only 17 joined. Participants received either hydroxychloroquine plus usual care or usual care alone for five days, and their health was tracked for 28 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Queen's Medical Center
Honolulu, Hawaii, 96813, United States
Conditions
Explore the condition pages connected to this study.